Prof. Dr.  

Matthias Augustin

, Germany


Presentations

Tips and tricks for a new registry: Why, when and how 12 October 2019 13:15 - 13:35 More ...
The value of indirect comparison and network meta-analysis methodologies in psoriasis for treatment decisions in clinical practice 10 October 2019 09:50 - 10:00 More ...
Pharmacovigilance of systemic antipsoriatic treatment: Results from more than 13,000 patient years in the German Psoriasis Registry PsoBest 10 October 2019 11:25 - 11:35 More ...
Patient Preferences for Treatment of Moderate to Severe Psoriasis: A Discrete Choice Experiment Study in Germany 11 October 2019 10:40 - 10:50 More ...
Significance and extent of stigmatization against persons with visible skin conditions in the public 12 October 2019 10:55 - 11:05 More ...
Dupilumab treatment for atopic dermatitis in Germany - disease burden and patient needs in routine care 09 October 2019 00:00 - 00:00 More ...
Study Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Impact of Apremilast on Quality of Life, Efficacy, and Safety in Patients With Specific Manifestations of Psoriasis and Impaired Quality of Life (EMBRACE) 09 October 2019 00:00 - 00:00 More ...
Effectiveness and safety of secukinumab in a real-world clinical setting in Europe: 1-year results from an interim analysis of the SERENA study 09 October 2019 00:00 - 00:00 More ...
Analysis of the Psoriasis Health Care Survey in 16 Latin American countries (pilot study) - the Global Psoriasis Atlas 09 October 2019 00:00 - 00:00 More ...
Secukinumab Treatment Resulted in Normalisation of Quality of Life in Moderate-to-severe Psoriasis Patients with or without Previous Systemic Therapy: Dermatology Life Quality Index Results from the PROSE Study 09 October 2019 00:00 - 00:00 More ...
Cumulative life course impairment CLCI - a concept supporting people-centered care in dermatology. 09 October 2019 00:00 - 00:00 More ...

Abstracts

Effectiveness and safety of secukinumab in a real-world clinical setting in Europe: 1-year results from an interim analysis of the SERENA study Psoriasis More
Analysis of the Psoriasis Health Care Survey in 16 Latin American countries (pilot study) - the Global Psoriasis Atlas Psoriasis More
Dupilumab treatment for atopic dermatitis in Germany - disease burden and patient needs in routine care Atopic Dermatitis/Eczema More
Secukinumab Treatment Resulted in Normalisation of Quality of Life in Moderate-to-severe Psoriasis Patients with or without Previous Systemic Therapy: Dermatology Life Quality Index Results from the PROSE Study Quality of Life More
Cumulative life course impairment CLCI - a concept supporting people-centered care in dermatology. Quality of Life More